Kornimate/medical-research-clean huggingface dataset:
canrenone as add-on in patients with essential hypertension

Conditions: Essential Hypertension

Summary: to evaluate the efficacy on blood pressure reduction, safety and tolerability of two different dosages of canrenone as add-on therapy in patients already treated with angiotensin converting-enzyme inhibitors (ace-i) or angiotensin ii receptor blockers (arbs) and diuretics at the maximum dosage.

to evaluate the efficacy on blood pressure reduction, safety and tolerability of two different dosages of canrenone as add-on therapy in patients already treated with angiotensin converting-enzyme inhibitors (ace-i) or angiotensin ii receptor blockers (arbs) and diuretics at the maximum dosage. in this multi-centre, phase iv, randomized, controlled, open-label, parallel groups trial, 180 caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ace-i or arbs and diuretics at the maximum dosage will be enrolled. at baseline patients will be randomized to canrenone, 50 mg, or canrenone 100 mg once a day, in addition to their current therapy, for three months. at the baseline, and after 3 months will be evaluated: systolic (sbp) and diastolic blood pressure (dbp), pulse pressure (pp), heart rate, fasting plasma glucose (fpg), homeostasis model assessment insulin (homa-index), total cholesterol, hdl-cholesterol, triglycerides, ldl-cholesterol, sodium, potassium, calcium, magnesium, uric acid, estimated glomerular filtration rate (egfr), plasmatic urea, brain natriuretic peptide (bnp), aldosterone, and galectin-3.

Eligibility criteria:
inclusion criteria: * caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ace-i or arbs and diuretics at the maximum dosage. exclusion criteria: * diabetes mellitus * secondary hypertension * pregnancy
caregiver experiences with tracheostomy

Conditions: Tracheostomy; Care Giving Burden; Caregiver

Summary: this study aimed to determine the experiences of primary caregivers of patients with tracheostomies on tracheostomy suctioning procedure. this is a semi-structured qualitative study.

the study sample consisted of eleven (11) primary caregivers of patients with tracheostomies who were hospitalized in the otolaryngology clinic of a university hospital in a province located in the northwest of turkey. this study was conducted using a semi-structured interview technique with the primary caregivers of the patients. interviews were audio-recorded during the data collection procedure. the content of the audio recordings obtained during each interview was evaluated by the researchers using the content analysis method. the data were categorized, coded, and analyzed by creating themes and sub-themes. it was observed that the primary caregivers of the patients expressed fear, sadness, and anxiety during the suctioning procedure performed by healthcare professionals or themselves during their hospitalization. it was determined that caregivers need information on suctioning practice and insufficient knowledge on emergencies worries them as well.

Eligibility criteria:
inclusion criteria: * being a caregiver of patients with tracheostomy over the age of 18 * volunteer. * being the primary caregiver of the patient, * ability to communicate verbally * normal psychological state. exclusion criteria: * being a caregiver of tracheostomy patients younger than 18 years of age * rejecting the voluntary event, * not being the primary caregiver of the patient, * inability to communicate verbally * having a psychological disorder

Keywords: tracheostomy suctioning caregiver
cardiac care solution for coronary disease follow up

Conditions: ST Segment Elevation Myocardial Infarction; Non-ST Segment Elevation Myocardial Infarction; Unstable Angina

Summary: this is a prospective, randomized controlled trial. the aim of the study is to evaluate the impacts of a cardiac post-discharge management solution in the secondary prevention of coronary artery disease (cad).

the aim of the study is to evaluate the impacts of a cardiac post-discharge management solution in the population of cardiovascular (cvd) patients who were discharged from the hospital. the objectives include two parts: objective 1: assess the feasibilities of using the solution by means of questionnaire. objective 2: evaluate the impacts of the solution in the secondary prevention of coronary artery disease (cad). primary outcome: compliance of coronary disease secondary prevention at 12 months. secondary outcome: compliance of coronary disease secondary prevention at 6 months. self-management behavior evaluation at the 6 and 12 months. medication compliance at 6 and 12 months assessed by self-reporting questionnaire. control rates of risk factors at the 6 and 12 months (serum ldl-c, blood pressure, fasting serum glucose); quality of life at the 6 and 12 months (eq-5d, seattle angina questionnaire); mace (major adverse cardiac event) within 12 months (death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for cardiac reason, unplanned coronary revascularization). the study will be a two arm, randomized control study. the intervention group will use an application installed on a pad besides standard outpatient follow up, while the control group will receive standard outpatient follow up.

Eligibility criteria:
inclusion criteria: * participants diagnosed with cad, including either condition below: once diagnosed with myocardial infarction; or once accepted coronary artery interventional therapy; * participants willing to use self-management solution and complying with follow-up plan; * at point of enrollment, the patients should be at least (\>=18) years * basic reading skills (chinese) exclusion criteria: * participants that are enrolled in another interventional clinical trial * participants who refuse to sign informed consent or withdraw for specific reasons recorded * participants who have cognition disorder and unable to communicate normally * participants who cannot master basic mobile technology skills to operate a mobile application after training
validation of the iga1 detection method with gradient glycosylation by mass spectrometry as a potential marker of renal involvement in pediatric rheumatoid purpura

Conditions: Rheumatoid Purpura; Pediatric ALL

Summary: in this ancillary study on the foxtreg cohort, the study investigators will select variables to input and thus develop two models (linear discriminant analysis and decision tree). the aim of this study is to validate the method in terms of repeatability, reproducibility, control of pre-analytical conditions and sample conservation, to complete the screening of iga glycosylation in individuals of the foxtreg cohort and to refine the glycopeptide signature to predict renal involvement.


Eligibility criteria:
inclusion criteria: patient sera from biobank of the foxtreg study (nct02317133)
a study of jnj-77242113 for the treatment of participants with moderate to severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the purpose of the study is to see how effective jnj-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.


Eligibility criteria:
inclusion criteria: * diagnosis of plaque psoriasis, with or without psoriatic arthritis (psa), for at least 26 weeks prior to the first administration of study intervention * total body surface area (bsa) greater than or equal to (\>=)10 percent (%) at screening and baseline * total psoriasis area and severity index (pasi) \>=12 at screening and baseline * total investigator global assessment (iga) \>=3 at screening and baseline * candidate for phototherapy or systemic treatment for plaque psoriasis exclusion criteria: * nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular) * current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) * a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * known allergies, hypersensitivity, or intolerance to jnj-77242113, deucravacitinib, or to any of the excipients or components of the study intervention * major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
sapphire worldwide: stenting and angioplasty with protection in patients at high-risk for endarterectomy

Conditions: Carotid Artery Disease

Summary: the primary objective of this study is to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease. the devices to be utilized are the cordis precise® nitinol stent systems (5.5f and 6f) and the cordis angioguard™ xp emboli capture guidewire (ecgw).

carotid artery stenting

Eligibility criteria:
inclusion criteria: * high-surgical risk patients to be treated consistent with ifu labeling * the patient or legally authorized representative has signed a written informed consent and hipaa authorization, prior to the procedure, using a form that is approved by the institutional review board or medical ethics committee. exclusion criteria: * patients not treated per the ifu * patients who are contraindicated per the ifu * patients previously enrolled in the study * patients requiring stenting of in-stent restenosis after cas * inability or refusal to provide informed consent.

Keywords: carotid artery stenting (endovascular)
ai-based prediction of lymph node metastasis in gastric cancer using preoperative multimodal data

Conditions: Gastric Cancer Adenocarcinoma Metastatic; Lymph Node Metastasis; Artificial Intelligence (AI) in Diagnosis

Summary: this study aims to develop and validate an artificial intelligence (ai) system that can predict whether lymph node metastasis has occurred in patients with gastric cancer before surgery. using preoperative imaging and pathology data, the ai models will not only predict if metastasis is present but also identify which specific lymph node stations or individual lymph nodes are involved. all lymph nodes will be carefully removed during surgery and examined one by one with detailed pathological methods to ensure accurate diagnosis. the goal is to improve the accuracy of lymph node assessment and assist doctors in making better treatment decisions.


Eligibility criteria:
inclusion criteria: * age 18 years or older histologically confirmed gastric adenocarcinoma scheduled for curative-intent gastrectomy with lymphadenectomy completed preoperative imaging with contrast-enhanced ct or mri available preoperative biopsy pathology report able and willing to provide written informed consent exclusion criteria: * evidence of distant metastasis on preoperative imaging prior chemotherapy, radiotherapy, or major abdominal surgery severe comorbidities contraindicating surgery incomplete or poor-quality preoperative imaging or pathology data pregnancy or lactation
the use of low molecular weight heparin in traumatic brain injury

Conditions: Brain Injury; Venous Thrombosis

Summary: to study the safety and efficacy of early administration of low molecular weight heparin to patients with traumatic brain injury.

venous thromboembolic (vte) prophylaxis in trauma patients is a critical clinical problem. patients with traumatic brain injury usually have effective vte prophylaxis withheld secondary to concerns of exacerbating intracranial hemorrhage. this study examines the safety and efficacy of early administration (within 24 hrs of admission) of low molecular weight heparin to this patient population with very high vte risk.

Eligibility criteria:
inclusion criteria: * blunt traumatic brain injury (marshall ii-v) * stable 6 hr. head ct * stable hemoglobin exclusion criteria: * premorbid coagulopathy * pregnancy * \< 18 y.o. * need for therapeutic anticoagulation * heparin allergy

Keywords: enoxaparin safety
the value of strem-1, pct, and crp as markers for the detection of sepsis and bacteremia among patients with a fuo

Conditions: SIRS; Sepsis; Bacteremia

Summary: the investigators enrolled 144 subjects admitted to icus: 60 patients with systemic inflammatory response syndrome (sirs) and 84 patients with sepsis. tests for serum strem-1, pct, and crp levels and blood culture were performed on the day of admission and with the occurrence of fuo (\>38.3ºc) during hospitalization. based on the results of blood culture, the subjects were divided into bacteremia (33 patients) and non-bacteremia groups (51 patients). based on 28-day survival, bacteremia patients were also divided into survivor (22 patients) and non-survivor groups (11 patients). serum strem-1 and pct levels were summarized as medians (interquartile ranges) and crp levels were presented as means ± standard deviations. to explore the early diagnostic value of soluble triggering receptor expressed on myeloid cells 1 (strem-1), procalcitonin (pct), and c-reactive protein (crp) serum levels for identification of sepsis and bacteremia and the prognosis among patients with a fever of unknown origin (fuo) in the intensive care unit (icu) and to discuss the clinical application of the results.


Eligibility criteria:
inclusion criteria: * male and female aged 18 years old and over; * clinically suspected infection; * fulfilled at least two criteria of systemic inflammatory response syndrome (a) core temperature higher than 38 °c or lower than 36 °c (b)respiratory rate above 20/min, or pco2 below 32 mmhg (c) pulse rate above 90/min, and (d) white blood cell count greater than 12,000/μl or lower than \< 4,000/μl or less than 10% of bands; * blood borne infections were diagnosed if the following criteria were met.(1) the blood culture tested positive at least for the same pathogen;(2) the patient had at least one of the following symptoms: fever, shivering, or low blood pressure and showed signs of at least one of the following conditions: the blood culture tested positive at least twice for common skin flora from different sites; the blood culture tested positive only once for the skin flora listed above, the intravascular catheter culture tested positive for the same pathogen and the correct antibiotic treatment had been initiated for the patient; or a positive serology test consistent with other clinical laboratory test results and unrelated to infections at different sites. exclusion criteria: those who fulfilled one below: * neutropenia (≤ 500 neutrophils/mm3) * hiv infection, and * patients or their relatives refused

Keywords: stre-1 pct crp sepsis bacteremia fuo diagnosis prognosis
a study to evaluate the safety of fycompa injection in participants with partial-onset seizures or primary generalized tonic- clonic seizures

Conditions: Partial-Onset Seizures; Primary Generalized Tonic-clonic Seizures

Summary: the purpose of this study is to determine the safety of fycompa for injection after administration in participants with epilepsy (partial-onset seizures \[including secondarily generalized seizures\]) (age 4 years or older) or primary generalized tonic-clonic seizures (age 12 years or older).


Eligibility criteria:
inclusion criteria: * participants with epilepsy who received the fycompa for injection for the first time will be included. exclusion criteria: * the exclusion criteria will not be specified in particular because this survey will be conducted in daily clinical practice.

Keywords: seizures secondarily generalized seizures fycompa
sternal hemostasis trial

Conditions: Excessive Bleeding During Surgery

Summary: sternal bleeding remains an unsolved problem for cardiac surgery teams costing operative time, blood loss, and distraction from the critical operative field. as such, the following is an investigator-initiated trial to determine whether application of a topical hemostatic agent reduces sternal bleeding during cardiac surgery using sternotomy approach.

this is a prospective randomized 1:1 trial to evaluate the efficacy of the application of hemoblasttm during cardiothoracic surgery to reduce the increased risk of sternal bleeding in 30 treatment and 30 control patients. enrollment will be open to all eligible participants undergoing cardiothoracic surgery who sign an informed consent. the study will also collect demographic data and relevant clinical data, such as medical history, diagnosis, family history, laboratory data, radiological images and reports, and diagnostic procedure reports. all enrolled subjects will be followed during their hospitalization until discharge for bleeding complications after their surgical procedure as well as a sternal bleeding spot grade tm score will be recorded independently by both the cardiac surgeon and assisting cardiothoracic pa-c, before and after the application of the topical hemostatic agent. there will be no restriction on the use of electrocautery or vancomycin paste as existing routine adjuncts used in cardiothoracic surgery for sternal hemostasis. chest tube output measurements will be collected at 6, 12, and 24 hours postoperatively. the patients will be assessed at the time of hospital discharge for any complications related to sternal or intrathoracic bleeding.

Eligibility criteria:
inclusion criteria: * patients are scheduled to undergo on-pump open chest cardiothoracic surgery. * patients must be willing and able to provide written informed consent. * if the patient is of childbearing potential, they must have a negative pregnancy test within 24 hours of the index procedure. * patients must be at least 21 years of age. * patients have at least one of the following risk factors: 1. undergoing redo sternotomy 2. have a preoperative platelet count \<150 mg/dl 3. are on dual antiplatelet therapy (blood thinners) \< 5 days prior to sternotomy 4. have a bmi (body mass index)\> 35 5. are undergoing combined cabg (coronary artery bypass surgery)/valve surgery 6. have chronic kidney disease (gfr \<60 ml/min) or esrd (end stage renal disease) exclusion criteria: * patients who undergo thoracotomy approach * patients who are not deemed an appropriate candidate by the investigator. * patients who are pregnant or nursing, or who plan to become pregnant during the course of this study.
examining the therapeutic potential of botulinum toxin type a in the treatment of keloids

Conditions: Keloid

Summary: keloids are a common form of hypertrophic scars that by definition last beyond 6 months and grow beyond the site of initial injury. keloids are a common complaint from patients in dermatology and cause significant functional impairment due to cosmetic disfigurement, itching and pain. current treatment modalities include intralesional corticosteroids, chemotherapeutic agents and laser therapy. initial reports have demonstrated that botulinum toxin type a may be a viable treatment option for keloids that can reduce keloid size and reduce associated symptoms while having fewer side effects when compared to intralesional corticosteroid injection, which can cause unnatural blood vessel growth or skin thinning. to date, no study has carefully examined the efficacy of botulinum toxin type a in treating keloids or its mechanistic effects on keloid biology. our aim in this study is to pursue a rigorous, randomized control trial to assess the potential use botulinum toxin type a to treat keloids. efficacy will be objectively be mentioned by change in keloid size after treatment, along with subjective measures of patient satisfaction and symptoms, and finally physician rated scores. also, samples from three patients will be analyzed in the laboratory setting to determine the underlying molecular mechanism behind the effects of botulinum toxin type a on keloid biology.


Eligibility criteria:
inclusion criteria: 1. adults aged 18 to 80 2. history of keloid scar for at least 12 months 3. absence of keloid treatment for past 12 months 4. participant must have a keloid scar of at least 4cm in length. 5. participants who score at least 8 or higher on the vancouver scar scale 6. subjects who score 5 (neither satisfied nor dissatisfied) to 10 (maximally dissatisfied) on the patient subjective score of dissatisfaction with keloid. 7. participants must be in stable health, as confirmed by medical history, per investigator judgment 8. participants must be able to read, sign, and understand the informed consent 9. participants must be willing to avoid any other treatments to the keloid that will be treated including corticosteroid injections, surgical excision, chemotherapeutic injection, lasers, light-based therapy, radiation therapy, cryotherapy, or pressure therapy, during the study period. exclusion criteria: 1. pregnant women 2. keloids on face, neck or scalp 3. history of hypersensitivity to botulinum toxin 4. ongoing or planned treatment with chemotherapy, radiation, isotretinoin, cytokine-based immunotherapies 5. any planned surgery during study period 6. known diagnosis of insulin dependent diabetes mellitus 7. patients being treating with dupilumab for any indication 8. patients taking aminoglycoside antibiotics 9. patients with pre-existing neuromuscular disorders 10. patients with infection around potential injection sites
nationwide research on the rewilding of kindergarten yards

Conditions: Microbial Colonization; Atopic Dermatitis; Asthma in Children; Allergy; Cognitive Change; Respiratory Infection; Nature, Human

Summary: biodiversity is essential for nature and human well-being. land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children. the investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children. our specific aims are: to assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms. assess whether the rewilding has positive effects on cognitive skills. assess whether the rewilding changes cortisol and plasma cytokine levels. the investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (task 1).


Eligibility criteria:
inclusion criteria: * attendance in kindergarten exclusion criteria: * use of antibiotics in the year before sampling

Keywords: commensal microbiome atopy planetary health biodiversity cognitive skills